 Dynavax and Novavax both reported Q4 2021 earnings after hours on 02282022 with heavy pandemic revenues, but only one had earnings. Both issued positive guidance as the state of the pandemic makes future vaccine uptake highly uncertain. Each has non-COVID irons in the fire. The alphavaxers present divergent paths to alpha, take your pick. 